Anaptysbio, Inc. · NASDAQ:ANAB
Anaptysbio — J.P. Morgan 38th Annual Healthcare Conference (January 2020)
34 slides from Anaptysbio's conference presentation, Jan 15, 2020
Slide 1: Corporate Overview
AnaptysBi oW Corporate Overview J.P. Morgan 38 Annual Healthcare Conference January 2020 Nasdaq: ANAB
Slide 2: Safe Harbor Statement
Safe Harbor Statement VY This presentation and the accompanying oral presentation contain “forward-looking” statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our
Slide 3: AnaptysBio: Clinical-Stage Novel Antibody R&D Engine
AnaptysBio: Clinical-Stage Novel Antibody R&D Engine VY Advancing First-In-Class Immunology Therapeutics to Patients Multiple Clinical Anticipated 2020 catalysts include: etokimab (CRSwNP Phase 2), ANBO19 Catalysts (GPP and PPP Phase 2), ANBO30 (Phase 1) and ANBO32 (IND filing) Rapid antibody R&D en
Slide 4: Wholly-Owned and Partnered Product Pipeline
Wholly-Owned and Partnered Product Pipeline 7 AnaptysBio-Generated Antibodies Advanced to Clinical Development Since 2016 Vv Development Stage & Anticipated Milestones antbody Program Therapetl ineation biecovery Predineal Phase phase Phases ‘CommerclalRlghte -AtopieDermatnis oKmaD(ANBI2O: ——sesmoph
Slide 5: Anticipated 2020 Wholly-Owned Pipeline Catalysts
Anticipated 2020 Wholly-Owned Pipeline Catalysts Y Program Milestone Timing ECLIPSE: Adult Chronic Rhinosinusitis ‘with Nasal Polyps Phase 2 Trial Interim top-line data anticipated in H1 2020 Etokimab (anti-IL-33) Moderate-to-Severe Eosinophilic ‘Asthma Phase 2b Trial inibaton- Foe pore Additional c
Slide 6: Wholly-Owned Pipeline: Etokimab (ANB020, Anti-IL-33)
AnaptysBioW : » Wholly-Owned Pipeline: Etokimab (ANBO020, Anti-IL-33) Chronic Rhinosinusitis with Nasal Polyps Moderate-to-Severe Eosinophilic Asthma
Slide 7: Etokimab: First-in-Class Anti-IL-33 Antibody
Etokimab: First-in-Class Anti-IL-33 Antibody VY Future Development Focused on Respiratory Indications IL-33 is genetically associated with asthma —_ 1L-83 pathway loss-of-function mutations protect against asthma, while gain-of-function mutations increase asthma incidence — Translational studies hav
Slide 8: ATLAS: Etokimab Atopic Dermatitis Phase 2b Trial
Top-line Data Announced November 2019 ATLAS: Etokimab Atopic Dermatitis Phase 2b Trial VY Treatment Period Monitoring Period Week 0 Etokimab 600mg SCLoading Dose + 300mg SC gw Maintenance Dose ——_4— | | | | Etokimab 300mg SCLoading Dose + 150mg SC q4w Maintenance Dose Etokimab 300mg SCLoading Dose +
Slide 9: Etokimab Development in Atopic Dermatitis Has Been Discontinued
Etokimab Development in Atopic Dermatitis Has Been Discontinued Vv ATLAS Trial Did Not Demonstrate Improvement Against Placebo Dose Group r % LS Mean Change % Blood Eosinophil : 7 Baseline EASI 2 : ‘ (patients randomized, see RelativetoBaselineat Change Relative to drop-out %) Week 16 (p value) Base
Slide 10: Etokimab Eosinophilic Asthma Phase 2a Trial
Etokimab Eosinophilic Asthma Phase 2a Trial VY Single Dose of Etokimab or Placebo Administered on Day 1 & a @ rs % go8 BS ob Be = 2 > ee & & 8 i BE g 8 , | Etokimab 300mg IV Single Dose + High Dose ICS/LABA n=12 Placebo Single Dose + High Dose ICS/LABA n=13 ‘Adults with severe asthma (according to G
Slide 11: FEV1 Improvement Relative to Baseline After Single Dose
FEV1 Improvement Relative to Baseline After Single Dose Rapid and Sustained Lung Function Improvement In Etokimab Arm 10% FEVL Improvement Relatveto Bexeine tes Timepoint tiokinae | racebo | net 1% pez | ux | ow | ox x 2 owe | ox x | o 5 # ox B Box z pase | ux | ox | ox EB 2% pes | asx | oe | uum &
Slide 12: Etokimab Arm Achieved MCID of 0.50 Score Reduction
Etokimab Arm Achieved Minimal Clinically Important Difference (MCID) of 0.50 Score Reduction Relative to Baseline ACQ-5 Score Reduction Relative to Baseline After Single Dose WZ ‘ACO-S Score Reduction Relative to Baseline (0.10) " ‘tokimab | Placebo | Net (0.20) Days 082 909 082 (0.30) Day22 043 025
Slide 13: ECLIPSE: Etokimab CRSwNP Phase 2 Trial
ECLIPSE: Etokimab CRSWNP Phase 2 Trial Interim Top-Line Data Anticipated H1 2020 VY Treatment Period ° ¢ Monitoring Period & 2 = = Etokimab 300mg SCLoading Dose + | 150mg SC q4w Maintenance Dose + MENS : Etokimab 300mg SCLoading Dose + | 150mg SC q8w Maintenance Dose + MFNS Placebo + MENS ———— MFNS
Slide 14: Wholly-Owned Pipeline: Anti-IL-36R (ANB019)
AnaptysBioW » ‘ ‘XN . ; Wholly-Owned Pipeline: \ \ y Anti-IL-36R (ANB019) ay Adult Generalized Pustular Psoriasis y Adult Palmoplantar Pustulosis |
Slide 15: IL-36 Dysfunction Mediates Severe Inflammatory Disease
IL-36 Dysfunction Mediates Severe Inflammatory Disease VY Genetic Association with Generalized Pustular Psoriasis Normal Individuals Disease Patients Treated Patients IL-36 cytokine signaling balanced by Mncormroed stones due to venom AntisL-26R antibody has the potential to “uncon ds receporanagons
Slide 16: Generalized Pustular Psoriasis (GPP)
Generalized Pustular Psoriasis (GPP) Y Orphan Disease Associated with IL-36 Receptor Antagonist Mutations - GPPis a systemic, life-threatening inflammatory disease characterized by widespread pustules - Patients have a high fever and elevated levels of serum CRP and inflammatory cytokines (e.g. IL-8
Slide 17: GALLOP: ANB019 Moderate-to-Severe GPP Phase 2 Trial
GALLOP: ANB019 Moderate-to-Severe GPP Phase 2 Trial VY Trial Design Treatment Period Monitoring Period ze 3 3 8, Se gs e - 7 = | ANBO19 750mg IV Loading Dose 2 + 100mg SC q4w Maintenance Dose Safient + Moderate-to-severe adult generalized pustular psoriasis patients is + Baseline mJDA score 27, 210%
Slide 18: ANB019 Monotherapy Resulted in Rapid and Sustained Improvement
ANBO019 Monotherapy Resulted in Rapid and Sustained Improvement VY Interim Analysis Conducted Using First Two Patients To Complete Day 113 Baseline Endp Result (average, where applicable) (average) Primary endpoint ‘Achieved by both patients Rescue therepy use None mJDA score (combines dermatologica
Slide 19: Interim Analysis Summary
Interim Analysis Summary VY Anticipate Additional Clinical Data and Regulatory Strategy Update in 2020 + Both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring rescue therapy + Patients demonstrated rapid and sustained mJDAscore improvement,
Slide 20: Palmoplantar Pustulosis (PPP)
Palmoplantar Pustulosis (PPP) Orphan Disease Associated With Elevated IL-36 Cytokine Levels Severe inflammation of hands and feet Significant pain and inability to stand, walk or work No approved therapeutic options in this indication PPP is an orphan disease that affects approximately 150,000 patie
Slide 21: POPLAR: ANB019 Palmoplantar Pustulosis Phase 2 Trial
POPLAR: ANB019 Palmoplantar Pustulosis Phase 2 Trial VY Top-Line Data Anticipated H2 2020 Treatment Period Monitoring Period Week Week 15 Week 24 ANBO19 200mg SC Loading Dose + | 100mg SC q4w Maintenance Dose Placebo _———————— el Patient e Adult Moderate-to-Severe Palmoplantar Pustulosis Population
Slide 22: Wholly-Owned Pipeline: Anti-PD-1 Agonist (ANB030), Anti-BTLA Modulator (ANB032)
AnaptysBioW < Wholly-Owned Pipeline: Anti-PD-1 Agonist (ANB030) W/ Anti-BTLA Modulator (ANB032) \ 7 Inflammatory Diseases
Slide 23: Anti-Inflammatory Checkpoint Receptor Antibodies
Anti-Inflammatory Checkpoint Receptor Antibodies Novel Therapeutic Class Validated By Human Genetics Anti-inflammatory checkpoint receptor antibodies have unique binding properties that are challenging to generate using traditional antibody technologies AnaptysBio’s technology platform has successfu
Slide 24: ANB030: PD-1 Agonist Antibody
ANBO030: PD-1 Agonist Antibody Novel Anti-Inflammatory Mechanism Applicable to T-Cell Driven Inflammatory Conditions Vv PD-1 is a key inhibitory immune checkpoint receptor responsible for down-regulating T-cell mediated immune responses Insufficient PD-1 activity is associated with human inflammator
Slide 25: ANB032: BTLA Modulator Antibody
Emerging Lymphoid and Myeloid Immune Control Mechanism Broadly Applicable to Inflammatory Disease ANBO032: BTLA Modulator Antibody ¥ ANBO32 BTLA is an inhibitory checkpoint receptor responsible for regulating activation of lymphoid (T and B) cells and myeloid (dendritic) cells + Genetic defects in t
Slide 26: Partnered Pipeline: GSK Immuno-Oncology Programs
AnaptysBioW Partnered Pipeline: GSK Immuno-Oncology Programs Dostarlimab (anti-PD-1 Antagonist) TSR-022 (anti-TIM-3 Antagonist) TSR-033 (anti-LAG-3 Antagonist)
Slide 27: GSK Immuno-Oncology Collaboration
GSK Immuno-Oncology Collaboration VY Dostarlimab Approaching US Regulatory Approval GARNET (n=740) Endometrial RUBY (n=470) FIRST (n=912) Key Deal Terms i + $18 ite milesto: Ovarian MOONSTONE (n=150) ee emmuestone - $432MM in potential om development/ regulatory NSCLC milestones oo - - $660MIM in po
Slide 28: Proprietary Technology Platform
AnaptysBioW Proprietary Technology Platform
Slide 29: Somatic Hypermutation (SHM) Platform
Somatic Hypermutation (SHM) Platform VY Proprietary Platform Incorporates in vitro SHM and Iterative Antibody Evolution In Vitro SHM. Iterative Antibody Evolution Y r Starting AID-Induced F L ibrary SHM a va 5 A)gp Selection a Optimized AlD-Induced Antibody SHM In vitro SHM permits access to biologi
Slide 30: Somatic Hypermutation (SHM) Platform: Advantages Over Competing Technologies
Somatic Hypermutation (SHM) Platform VY Advantages Over Competing Antibody Technologies Unprecedented antibody diversity through SHM — In situantibody diversity generation outside of the constraints of an in vivo environment High potency & functional activity — Only small doses may be required to co
Slide 31: Summary
AnaptysBioW N N Summary
Slide 32: Anticipated 2020 Wholly-Owned Pipeline Catalysts
Anticipated 2020 Wholly-Owned Pipeline Catalysts VY Program Milestone Timing ECLIPSE: Adult Chronic Rhinosinusitis ‘with Nasal Polyps Phase 2 Trial Interim top-line data anticipated in H1 2020 Etokimab (anti-IL-33) Moderate-to-Severe Eosinophilic ‘Asthma Phase 2b Trial insiation: Postponed Additiona
Slide 33: AnaptysBio: Clinical-Stage Novel Antibody R&D Engine
AnaptysBio: Clinical-Stage Novel Antibody R&D Engine VY Advancing First-In-Class Immunology Therapeutics to Patients Multiple Clinical Anticipated 2020 catalysts include: etokimab (CRSwNP Phase 2), ANBO19 Catalysts (GPP and PPP Phase 2), ANBO30 (Phase 1) and ANBO32 (IND filing) Rapid antibody R&D en
Slide 34: AnaptysBioW \e
AnaptysBioW \e
Anaptysbio — J.P. Morgan 38th Annual Healthcare Conference (January 2020) on 6ix